SRR26320065
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.450
- FATTY_ACID_METABOLISM+0.410
- PROTEIN_SECRETION+0.410
- OXIDATIVE_PHOSPHORYLATION+0.400
- G2M_CHECKPOINT+0.360
- DNA_REPAIR+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.310
- PEROXISOME+0.300
- MTORC1_SIGNALING+0.280
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.440
- HEDGEHOG_SIGNALING-0.410
- COAGULATION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- MYOGENESIS-0.390
- NOTCH_SIGNALING-0.390
- TNFA_SIGNALING_VIA_NFKB-0.370
- APICAL_SURFACE-0.310
- IL6_JAK_STAT3_SIGNALING-0.310
- APICAL_JUNCTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202421 | — | — | 0.918 |
| 2 | DRR168601 | — | — | 0.896 |
| 3 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.888 |
| 4 | SRR8518448 | — | C | 0.887 |
| 5 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.885 |
| 6 | TCGA-A8-A06O-01A-11R-A00Z-07 | — | B | 0.884 |
| 7 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.883 |
| 8 | TCGA-CU-A3QU-01A-11R-A22U-07 | — | — | 0.883 |
| 9 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.882 |
| 10 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |